查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566307

恶性肋膜间质细胞瘤的全球市场：按药物类型、给药途径、通路、地区和国家分類的分析、市场考虑因素和预测

Global Malignant Pleural Mesothelioma Market : Analysis By Drug Type, By Route of Administration, By Distribution Channel, By Region, By Country: Market Insights and Forecast
出版日期: | 出版商: Azoth Analytics | 英文 259 Pages | 订单完成后即时交付

价格

预计2023年全球恶性肋膜间质细胞瘤市场规模为6.4899亿美元，2020-2023年复合年增长率为4.98%，预计2030年将达到10.4569亿美元。

由于多个关键因素，全球恶性肋膜间质细胞瘤市场预计将在预测期内显着成长。最重要的影响因素之一是石棉相关疾病的盛行率增加，特别是在历史上使用石棉的地区。据世界卫生组织 (WHO) 称，石棉仍然是间皮瘤的主要原因，并且在某些地区有持续存在的风险。

免疫疗法和基因疗法等创新治疗方法也透过为患者提供改善的结果和新的希望来促进市场成长。这些新治疗方法正在获得关注，特别是在已开发地区，先进的医疗基础设施支持采用最先进治疗。提高宣导活动有助于提高早期发现率，进一步提高这些治疗方法的有效性。

此外，新兴市场不断扩大的医疗基础设施正在增加获得先进诊断和治疗选择的机会，从而推动市场成长。

该报告探讨了全球恶性肋膜间质细胞瘤市场，并提供包括市场规模和预测、区域和細項分析以及主要趋势和机会在内的资讯。

目录

第一章 市集背景

  • 产品范围和产品前景
  • 执行摘要
  • 调查方法

第二章 分析师建议

  • 扩大新给药途径的临床试验
  • 利用亚太和拉丁美洲的新兴市场

第三章全球恶性肋膜间质细胞瘤市场：表现与预测

  • 宏观经济因素对恶性肋膜间质细胞瘤市场的影响分析
  • 主要石棉出口国：依国家分类（2021 年）
  • 主要石棉进口国：依国家分类（2021 年）
  • 间皮瘤的盛行率和发生率（2018-2021）
  • 全球恶性肋膜间质细胞瘤市场：仪表板
  • 全球恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
  • 全球恶性肋膜间质细胞瘤市场：市场金额评估
  • 按药物类型分類的全球恶性肋膜间质细胞瘤市场细分
    • 全球恶性肋膜间质细胞瘤市场：依药物类型概述
    • 按药物类型分類的全球恶性肋膜间质细胞瘤市场吸引力指数
    • 全球恶性肋膜间质细胞瘤市场规模：Pemetrexed合併用药（2020-2030）
    • 全球恶性肋膜间质细胞瘤市场规模：Cisplatin（2020-2030）
    • 全球恶性肋膜间质细胞瘤市场规模：Carboplatin（2020-2030）
    • 全球恶性肋膜间质细胞瘤市场规模：Gemcitabine（2020-2030）
    • 全球恶性肋膜间质细胞瘤市场规模：Vinorelbine（2020-2030）
    • 全球恶性肋膜间质细胞瘤市场规模：其他药物类型（2020-2030）
  • 按给药途径的全球恶性肋膜间质细胞瘤市场细分
    • 全球恶性肋膜间质细胞瘤市场：依给药途径概述
    • 全球恶性肋膜间质细胞瘤市场吸引力指数：依给药途径分类
    • 全球恶性肋膜间质细胞瘤市场规模：口服（2020-2030）
    • 全球恶性肋膜间质细胞瘤市场规模：胃肠外（2020-2030）
  • 按分销管道分類的全球恶性肋膜间质细胞瘤市场细分
    • 全球恶性肋膜间质细胞瘤市场：按分销管道分類的概述
    • 全球恶性肋膜间质细胞瘤市场吸引力指数：按分销管道划分
    • 全球恶性肋膜间质细胞瘤市场规模：医院药局（2020-2030）
    • 全球恶性肋膜间质细胞瘤市场规模：零售药局、网路药局（2020-2030）

第四章恶性肋膜间质细胞瘤市场，区域分析

  • 研究的区域范围
  • 区域简介

第五章美洲恶性肋膜间质细胞瘤市场：表现与预测

  • 美洲恶性肋膜间质细胞瘤市场：概况
  • 美洲恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
  • 美洲恶性肋膜间质细胞瘤市场：主要驱动因素
  • 美洲恶性肋膜间质细胞瘤市场：細項分析
  • 按药物类型分類的美洲恶性肋膜间质细胞瘤市场细分
  • 按给药途径的美洲恶性肋膜间质细胞瘤市场细分
  • 按分销管道分類的美洲恶性肋膜间质细胞瘤市场细分
  • 按国家/地区分類的美洲恶性肋膜间质细胞瘤市场细分
    • 美洲恶性肋膜间质细胞瘤市场：按国家/地区划分，概述
    • 美国恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 加拿大恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 其他美洲恶性肋膜间质细胞瘤市场：市场规模和复合年增长率（2020-2030）

第六章欧洲恶性肋膜间质细胞瘤市场：表现与预测

  • 欧洲恶性肋膜间质细胞瘤市场：简介
  • 欧洲恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
  • 欧洲恶性肋膜间质细胞瘤市场：关键驱动因素
  • 欧洲恶性肋膜间质细胞瘤市场：細項分析
  • 按药物类型分類的欧洲恶性肋膜间质细胞瘤市场细分
  • 按给药途径的欧洲恶性肋膜间质细胞瘤市场细分
  • 欧洲恶性肋膜间质细胞瘤细分市场：按分销管道
  • 欧洲恶性肋膜间质细胞瘤市场细分：依国家分类
    • 欧洲恶性肋膜间质细胞瘤市场：逐国概述
    • 英国恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 德国恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 法国恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 义大利恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 西班牙恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 其他欧洲恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）

第七章亚太地区恶性肋膜间质细胞瘤市场：实际与预测

  • 亚太地区恶性肋膜间质细胞瘤市场：概述
  • 亚太地区恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
  • 亚太地区恶性肋膜间质细胞瘤市场：主要驱动因素
  • 亚太地区恶性肋膜间质细胞瘤市场：細項分析
  • 按药物类型分類的亚太地区恶性肋膜间质细胞瘤市场细分
  • 依给药途径的亚太地区恶性肋膜间质细胞瘤市场细分
  • 按分销管道分類的亚太地区恶性肋膜间质细胞瘤市场细分
  • 按国家/地区分類的亚太地区恶性肋膜间质细胞瘤市场细分
    • 亚太地区恶性肋膜间质细胞瘤市场：按国家/地区划分，概述
    • 中国恶性肋膜间质细胞瘤市场：市场规模及复合年增长率（2020-2030）
    • 印度恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 日本恶性肋膜间质细胞瘤市场：市场规模与复合年增长率（2020-2030）
    • 其他亚太地区恶性肋膜间质细胞瘤市场：市场规模和复合年增长率（2020-2030）

第八章中东与非洲恶性肋膜间质细胞瘤市场：表现与预测

  • 中东和非洲恶性肋膜间质细胞瘤市场：概况
  • 中东和非洲恶性肋膜间质细胞瘤市场：市场规模和复合年增长率（2020-2030）
  • 中东和非洲恶性肋膜间质细胞瘤市场：主要驱动因素
  • 中东和非洲恶性肋膜间质细胞瘤市场：細項分析
  • 中东和非洲恶性肋膜间质细胞瘤市场细分（按药物类型）
  • 中东和非洲恶性肋膜间质细胞瘤市场细分（按给药途径）
  • 中东和非洲恶性肋膜间质细胞瘤市场细分（按分销管道）

第九章市场动态

  • 评估市场动态对恶性肋膜间质细胞瘤市场的影响
  • 促进因素
  • 抑制因素
  • 趋势

第10章产业生态系分析

  • 波特分析

第十一章竞争定位

  • 企业产品定位
  • 市场地位矩阵
  • 恶性肋膜间质细胞瘤市场占有率分析
  • 公司简介
    • Bristol Myers Squibb
    • F. Hoffmann-La Roche AG
    • Merck & Co., Inc
    • Eli Lily & Co.
    • Pfizer
    • Novartis
    • Teva Pharmaceuticals
    • GSK plc
    • AstraZeneca PLC
    • Bayer AG

第十二章 关于我们公司、免责声明

Executive Summary

Azoth Analytics has released a research report titled "Global Malignant Pleural Mesothelioma Market (2024 Edition)" which provides a Pemetrexed and Combination analysis of the Global Malignant Pleural Mesothelioma industry in terms of market segmentation By Drug Type (Pemetrexed and Combination, Cisplatin), By Route of Administration (Oral, Parenteral) By Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy) for the historical period of 2020-2023, the estimates of 2024 and the forecast period of 2025-2030.

The report analyses the Malignant Pleural Mesothelioma Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India). The Global Malignant Pleural Mesothelioma market showcased growth at a CAGR of 4.98% during 2020-2023. The market was valued at USD 648.99 Million in 2023 which is expected to reach USD 1045.69 Million in 2030.

The global Malignant Pleural Mesothelioma market is projected to experience significant growth during the forecast period, driven by several key factors. Among the most prominent drivers is the increasing incidence of asbestos-related diseases, particularly in regions with historical asbestos use. According to the World Health Organization (WHO), asbestos remains the primary cause of mesothelioma, underscoring the persistent risk in certain regions.

Innovative treatment options, such as immunotherapy and gene therapy, are also contributing to market expansion by offering improved outcomes and new hope for patients. These novel therapies are gaining traction, especially in developed regions, where advanced healthcare infrastructure supports the adoption of cutting-edge treatments. Rising awareness campaigns are helping improve early detection rates, further enhancing the effectiveness of these therapies.

Furthermore, the growing healthcare infrastructure in emerging markets is enabling greater access to advanced diagnostic and treatment options, fueling market growth.

Scope of the Report:

  • The report analyses the Malignant Pleural Mesothelioma Market by Value (USD Million).
  • The report analyses the Malignant Pleural Mesothelioma Market by Region (Americas, Europe, Asia Pacific, Middle East & Africa) and 10 Countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, Japan, India).
  • The report presents the analysis of Malignant Pleural Mesothelioma Market for the historical period of 2020-2023, the estimated year 2024 and the forecast period of 2025-2030.
  • The report analyses the Malignant Pleural Mesothelioma Market By Drug Type (Pemetrexed and Combination, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Other Drug Types)
  • The report analyses the Malignant Pleural Mesothelioma Market By Route of Administration (Oral, and Parenteral).
  • The report analyses the Malignant Pleural Mesothelioma Market By Distribution Channel (Hospital Pharmacy, Retail & Online Pharmacy).
  • The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, By Drug Type, By Route of Administration and By Distribution Channel.
  • Also, the major opportunities, trends, drivers, and challenges of the industry has been analyzed in the report.
  • The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analyzed in the report include Bristol Myers Squibb, F. Hoffmann-La Roche AG, Merck & Co., Inc, Eli Lily & Co., Pfizer, Novartis, Teva Pharmaceuticals, GSK plc, AstraZeneca PLC, and Bayer AG

Table of Contents

1. Market Background

  • 1.1 Scope and Product Outlook
  • 1.2 Executive Summary
  • 1.3 Research Methodology

2. Analyst Recommendations

  • 2.1 Expanding Clinical Trials for Novel Route of Administration
  • 2.2 Capitalizing on Emerging Markets in Asia-Pacific and Latin America

3. Global Malignant Pleural Mesothelioma Market: Historic and Forecast

  • 3.1 Impact Analysis of Macro Economic Factors on Malignant Pleural Mesothelioma Market
  • 3.2 Top exporters of Asbestos by country in 2021
  • 3.3 Top Importer of Asbestos by country in 2021
  • 3.4 Prevalence and Incidence of Mesothelioma 2018-2021
  • 3.5 Global Malignant Pleural Mesothelioma Market: Dashboard
  • 3.6 Global Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 3.7 Global Malignant Pleural Mesothelioma Market: Market Value Assessment
  • 3.8 Global Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
    • 3.8.1 Global Malignant Pleural Mesothelioma Market, By Drug Type Overview
    • 3.8.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Drug Type
    • 3.8.3 Global Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.4 Global Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.5 Global Malignant Pleural Mesothelioma Market Size, By Carboplatin , By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.6 Global Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.7 Global Malignant Pleural Mesothelioma Market Size, By Vinorelbine , By Value, 2020H-2030F (USD Million & CAGR)
    • 3.8.8 Global Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.9 Global Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
    • 3.9.1 Global Malignant Pleural Mesothelioma Market, By Route of Administration Overview
    • 3.9.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Route of Administration
    • 3.9.3 Global Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.9.4 Global Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 3.10 Global Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
    • 3.10.1 Global Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
    • 3.10.2 Global Malignant Pleural Mesothelioma Market Attractiveness Index, By Distribution Channel
    • 3.10.3 Global Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
    • 3.10.4 Global Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)

4. Malignant Pleural Mesothelioma Market, Region Analysis

  • 4.1 Regional Coverage of the Study
  • 4.2 Regional Snapshot

5. Americas Malignant Pleural Mesothelioma Market: Historic and Forecast

  • 5.1 Americas Malignant Pleural Mesothelioma Market: Snapshot
  • 5.2 Americas Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 5.3 Americas Malignant Pleural Mesothelioma Market: Key Factors
  • 5.4 Americas Malignant Pleural Mesothelioma Market: Segment Analysis
  • 5.5 Americas Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
    • 5.5.1 Americas Malignant Pleural Mesothelioma Market, By Drug Type Overview
    • 5.5.2 Americas Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.3 Americas Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.4 Americas Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.5 Americas Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.6 Americas Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.5.7 Americas Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.6 Americas Malignant Pleural Mesothelioma Market Segmentation: Route of Administration
    • 5.6.1 Americas Malignant Pleural Mesothelioma Market, By Route of Administration Overview
    • 5.6.2 Americas Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.6.3 Americas Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.7 Americas Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
    • 5.7.1 Americas Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
    • 5.7.2 Americas Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
    • 5.7.3 Americas Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 5.8 Americas Malignant Pleural Mesothelioma Market Segmentation: By Country
    • 5.8.1 Americas Malignant Pleural Mesothelioma Market, by Country Overview
    • 5.8.2 United States Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.8.2.1 United States Malignant Pleural Mesothelioma Market, By Drug Type
      • 5.8.2.2 United States Malignant Pleural Mesothelioma Market, By Route of Administration
      • 5.8.2.3 United States Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 5.8.3 Canada Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.8.3.1 Canada Malignant Pleural Mesothelioma Market, By Drug Type
      • 5.8.3.2 Canada Malignant Pleural Mesothelioma Market, By Route of Administration
      • 5.8.3.3 Canada Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 5.8.4 Rest of Americas Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 5.8.4.1 Rest of Americas Malignant Pleural Mesothelioma Market, By Drug Type
      • 5.8.4.2 Rest of Americas Malignant Pleural Mesothelioma Market, By Route of Administration
      • 5.8.4.3 Rest of Americas Malignant Pleural Mesothelioma Market, By Distribution Channel

6. Europe Malignant Pleural Mesothelioma Market: Historic and Forecast

  • 6.1 Europe Malignant Pleural Mesothelioma Market: Snapshot
  • 6.2 Europe Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 6.3 Europe Malignant Pleural Mesothelioma Market: Key Factors
  • 6.4 Europe Malignant Pleural Mesothelioma Market: Segment Analysis
  • 6.5 Europe Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
    • 6.5.1 Europe Malignant Pleural Mesothelioma Market, By Drug Type Overview
    • 6.5.2 Europe Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.3 Europe Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.4 Europe Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.5 Europe Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.6 Europe Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.5.7 Europe Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.6 Europe Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
    • 6.6.1 Europe Malignant Pleural Mesothelioma Market, By Route of Administration Overview
    • 6.6.2 Europe Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.6.3 Europe Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.7 Europe Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
    • 6.7.1 Europe Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
    • 6.7.2 Europe Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
    • 6.7.3 Europe Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 6.8 Europe Malignant Pleural Mesothelioma Market Segmentation: By Country
    • 6.8.1 Europe Malignant Pleural Mesothelioma Market, by Country Overview
    • 6.8.2 United Kingdom Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.8.2.1 United Kingdom Malignant Pleural Mesothelioma Market, By Drug Type
      • 6.8.2.2 United Kingdom Malignant Pleural Mesothelioma Market, By Route of Administration
      • 6.8.2.3 United Kingdom Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 6.8.3 Germany Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.8.3.1 Germany Malignant Pleural Mesothelioma Market, By Drug Type
      • 6.8.3.2 Germany Malignant Pleural Mesothelioma Market, By Route of Administration
      • 6.8.3.3 Germany Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 6.8.4 France Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.8.4.1 France Malignant Pleural Mesothelioma Market, By Drug Type
      • 6.8.4.2 France Malignant Pleural Mesothelioma Market, By Route of Administration
      • 6.8.4.3 France Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 6.8.5 Italy Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.8.5.1 Italy Malignant Pleural Mesothelioma Market, By Drug Type
      • 6.8.5.2 Italy Malignant Pleural Mesothelioma Market, By Route of Administration
      • 6.8.5.3 Italy Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 6.8.6 Spain Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.8.6.1 Spain Malignant Pleural Mesothelioma Market, By Drug Type
      • 6.8.6.2 Spain Malignant Pleural Mesothelioma Market, By Route of Administration
      • 6.8.6.3 Spain Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 6.8.7 Rest of Europe Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 6.8.7.1 Rest of Europe Malignant Pleural Mesothelioma Market, By Drug Type
      • 6.8.7.2 Rest of Europe Malignant Pleural Mesothelioma Market, By Route of Administration
      • 6.8.7.3 Rest of Europe Malignant Pleural Mesothelioma Market, By Distribution Channel

7. Asia Pacific Malignant Pleural Mesothelioma Market: Historic and Forecast

  • 7.1 Asia Pacific Malignant Pleural Mesothelioma Market: Snapshot
  • 7.2 Asia Pacific Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 7.3 Asia Pacific Malignant Pleural Mesothelioma Market: Key Factors
  • 7.4 Asia Pacific Malignant Pleural Mesothelioma Market: Segment Analysis
  • 7.5 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
    • 7.5.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type Overview
    • 7.5.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.4 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.5 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.6 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.5.7 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.6 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
    • 7.6.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration Overview
    • 7.6.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.6.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.7 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
    • 7.7.1 Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
    • 7.7.2 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
    • 7.7.3 Asia Pacific Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
  • 7.8 Asia Pacific Malignant Pleural Mesothelioma Market Segmentation: By Country
    • 7.8.1 Asia Pacific Malignant Pleural Mesothelioma Market, by Country Overview
    • 7.8.2 China Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.8.2.1 China Malignant Pleural Mesothelioma Market, By Drug Type
      • 7.8.2.2 China Malignant Pleural Mesothelioma Market, By Route of Administration
      • 7.8.2.3 China Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 7.8.3 India Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.8.3.1 India Malignant Pleural Mesothelioma Market, By Drug Type
      • 7.8.3.2 India Malignant Pleural Mesothelioma Market, By Route of Administration
      • 7.8.3.3 India Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 7.8.4 Japan Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.8.4.1 Japan Malignant Pleural Mesothelioma Market, By Drug Type
      • 7.8.4.2 Japan Malignant Pleural Mesothelioma Market, By Route of Administration
      • 7.8.4.3 Japan Malignant Pleural Mesothelioma Market, By Distribution Channel
    • 7.8.5 Rest of Asia Pacific Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
      • 7.8.5.1 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type
      • 7.8.5.2 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration
      • 7.8.5.3 Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel

8. Middle East and Africa Malignant Pleural Mesothelioma Market: Historic and Forecast

  • 8.1 Middle East and Africa Malignant Pleural Mesothelioma Market: Snapshot
  • 8.2 Middle East and Africa Malignant Pleural Mesothelioma Market: Market Size and CAGR, 2020-2030 (USD Million & CAGR)
  • 8.3 Middle East and Africa Malignant Pleural Mesothelioma Market: Key Factors
  • 8.4 Middle East and Africa Malignant Pleural Mesothelioma Market: Segment Analysis
  • 8.5 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Drug Type
    • 8.5.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Drug Type Overview
    • 8.5.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.4 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.5 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.6 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.5.7 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.6 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Route of Administration
    • 8.6.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Route of Administration Overview
    • 8.6.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.6.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Million & CAGR)
  • 8.7 Middle East and Africa Malignant Pleural Mesothelioma Market Segmentation: By Distribution Channel
    • 8.7.1 Middle East and Africa Malignant Pleural Mesothelioma Market, By Distribution Channel Overview
    • 8.7.2 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)
    • 8.7.3 Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Million & CAGR)

9. Market Dynamics

  • 9.1 Impact assessment of Market Dynamics on Malignant Pleural Mesothelioma Market
  • 9.2 Drivers
  • 9.3 Restraints
  • 9.4 Trends

10. Industry Ecosystem Analysis

  • 10.1 Porter Analysis

11. Competitive Positioning

  • 11.1 Companies' Product Positioning
  • 11.2 Market Position Matrix
  • 11.3 Market Share Analysis of Malignant Pleural Mesothelioma Market
  • 11.4 Company Profiles
    • 11.4.1 Bristol Myers Squibb
    • 11.4.2 F. Hoffmann-La Roche AG
    • 11.4.3 Merck & Co., Inc
    • 11.4.4 Eli Lily & Co.
    • 11.4.5 Pfizer
    • 11.4.6 Novartis
    • 11.4.7 Teva Pharmaceuticals
    • 11.4.8 GSK plc
    • 11.4.9 AstraZeneca PLC
    • 11.4.10 Bayer AG

12. About Us & Disclaimer

List of Figures

  • Figure 1: Global Prevalence and Incidence of Mesothelioma 2018-2021
  • Figure 2: Global Malignant Pleural Mesothelioma Market Size, By Value, 2020-2023 (USD Million)
  • Figure 3: Global Malignant Pleural Mesothelioma Market Size, By Value, 2024-2030 (USD Million)
  • Figure 4: Global Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
  • Figure 5: Market Attractiveness Analysis of Malignant Pleural Mesothelioma Market, By Drug Type (2025-2030)
  • Figure 6: Global Malignant Pleural Mesothelioma Market Size, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 7: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Pemetrexed and Combination , 2020-2030 (USD Million)
  • Figure 8: Global Malignant Pleural Mesothelioma Market Size, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 9: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Cisplatin, 2020-2030 (USD Million)
  • Figure 10: Global Malignant Pleural Mesothelioma Market Size, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 11: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Carboplatin, 2020-2030 (USD Million)
  • Figure 12: Global Malignant Pleural Mesothelioma Market Size, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 13: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Gemcitabine, 2020-2030 (USD Million)
  • Figure 14: Global Malignant Pleural Mesothelioma Market Size, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 15: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Vinorelbine, 2020-2030 (USD Million)
  • Figure 16: Global Malignant Pleural Mesothelioma Market Size, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 17: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Other Drug Types, 2020-2030 (USD Million)
  • Figure 18: Market Attractiveness Analysis of Malignant Pleural Mesothelioma Market, By Route of Administration (2025-2030)
  • Figure 19: Global Malignant Pleural Mesothelioma Market Size, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 20: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Oral, 2020-2030 (USD Million)
  • Figure 21: Global Malignant Pleural Mesothelioma Market Size, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 22: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Parenteral, 2020-2030 (USD Million)
  • Figure 23: Market Attractiveness Analysis of Malignant Pleural Mesothelioma Market, By Distribution Channel (2025-2030)
  • Figure 24: Global Malignant Pleural Mesothelioma Market Size, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 25: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Hospital Pharmacy, 2020-2030 (USD Million)
  • Figure 26: Global Malignant Pleural Mesothelioma Market Size, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 27: Global Malignant Pleural Mesothelioma Market Absolute Opportunity, By Retail & Online Pharmacy, 2020-2030 (USD Million)
  • Figure 28: Americas Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 29: Americas Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
  • Figure 30: Americas Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 31: Americas Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 32: Americas Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 33: Americas Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 34: Americas Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 35: Americas Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 36: Americas Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 37: Americas Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 38: Americas Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 39: Americas Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 40: United States Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 41: United States Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 42: United States Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 43: United States Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 44: United States Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 45: Canada Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 46: Canada Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 47: Canada Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 48: Canada Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 49: Canada Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 50: Rest of Americas Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 51: Rest of Americas Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 52: Rest of Americas Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 53: Rest of Americas Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 54: Rest of Americas Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 55: Europe Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 56: Europe Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
  • Figure 57: Europe Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 58: Europe Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 59: Europe Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 60: Europe Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 61: Europe Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 62: Europe Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 63: Europe Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 64: Europe Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 65: Europe Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 66: Europe Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 67: United Kingdom Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 68: United Kingdom Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 69: United Kingdom Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 70: United Kingdom Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 71: United Kingdom Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 72: Germany Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 73: Germany Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 74: Germany Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 75: Germany Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 76: Germany Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 77: France Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 78: France Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 79: France Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 80: France Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 81: France Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 82: Italy Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 83: Italy Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 84: Italy Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 85: Italy Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 86: Italy Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 87: Spain Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 88: Spain Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 89: Spain Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 90: Spain Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 91: Spain Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 92: Rest of Europe Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 93: Rest of Europe Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 94: Rest of Europe Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 95: Rest of Europe Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 96: Rest of Europe Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 97: Asia Pacific Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 98: Asia Pacific Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
  • Figure 99: Asia Pacific Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 100: Asia Pacific Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 101: Asia Pacific Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 102: Asia Pacific Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 103: Asia Pacific Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 104: Asia Pacific Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 105: Asia Pacific Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 106: Asia Pacific Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 107: Asia Pacific Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 108: Asia Pacific Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 109: China Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 110: China Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 111: China Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 112: China Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 113: China Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 114: India Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 115: India Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 116: India Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 117: India Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 118: India Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 119: Japan Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 120: Japan Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 121: Japan Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 122: Japan Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 123: Japan Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 124: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Value, 2020-2030 (USD Millions & CAGR)
  • Figure 125: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Value, By Route of Administration, 2023 (USD Million)
  • Figure 126: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Share, By Drug Type, By Value, 2023 (%)
  • Figure 127: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Share, By Route of Administration, By Value, 2023 (%)
  • Figure 128: Rest of Asia Pacific Malignant Pleural Mesothelioma Market Share, By Distribution Channel, By Value, 2023 (%)
  • Figure 129: Middle East and Africa Malignant Pleural Mesothelioma Market Size, By Value, 2020H-2030F (USD Million)
  • Figure 130: Middle East and Africa Malignant Pleural Mesothelioma Market Share, By Distribution Channel, 2023 (%)
  • Figure 131: Middle East and Africa Malignant Pleural Mesothelioma Market, By Pemetrexed and Combination , By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 132: Middle East and Africa Malignant Pleural Mesothelioma Market, By Cisplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 133: Middle East and Africa Malignant Pleural Mesothelioma Market, By Carboplatin, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 134: Middle East and Africa Malignant Pleural Mesothelioma Market, By Gemcitabine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 135: Middle East and Africa Malignant Pleural Mesothelioma Market, By Vinorelbine, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 136: Middle East and Africa Malignant Pleural Mesothelioma Market, By Other Drug Types, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 137: Middle East and Africa Malignant Pleural Mesothelioma Market, By Oral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 138: Middle East and Africa Malignant Pleural Mesothelioma Market, By Parenteral, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 139: Middle East and Africa Malignant Pleural Mesothelioma Market, By Hospital Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 140: Middle East and Africa Malignant Pleural Mesothelioma Market, By Retail & Online Pharmacy, By Value, 2020H-2030F (USD Millions & CAGR)
  • Figure 141: Market Share of Prominent Companies of Malignant Pleural Mesothelioma Market, 2023 (%)
  • Figure 142: Bristol Myers Squibb Revenues, 2021-2023 (USD Million)
  • Figure 143: Bristol Myers Squibb Revenues, By Geographic Segments, 2023 (%)
  • Figure 144: Bristol Myers Squibb Revenue , By Products, 2023 (%)
  • Figure 145: Roche Revenues, 2021-2023 (USD Million)
  • Figure 146: Roche Revenue , By Sales Division, 2023 (%)
  • Figure 147: Roche Revenue , By Geographical Segment, 2023 (%)
  • Figure 148: Merck & Co., Inc. Revenues, 2021-2023 (USD Million)
  • Figure 149: Merck & Co., Inc. Revenues, By Geographic Segments, 2023 (%)
  • Figure 150: Merck & Co., Inc. Revenue , By Business Segments, 2023 (%)
  • Figure 151: Eli Lily & Co. Revenues, 2021-2023 (USD Million)
  • Figure 152: Eli Lily & Co. Revenues, By Geographic Segments, 2023 (%)
  • Figure 153: Eli Lily & Co. Revenue , By Business Segments, 2023 (%)
  • Figure 154: Pfizer Revenues, 2020-2022 (USD Million)
  • Figure 155: Pfizer Revenues, By Business Segments, 2023 (%)
  • Figure 156: Pfizer Inc. Revenue , By Geographical Segments, 2023 (%)
  • Figure 157: Novartis Revenues, 2021-2023 (USD Million)
  • Figure 158: Novartis Revenues, By Geographic Segments, 2023 (%)
  • Figure 159: Novartis Revenue , By Business Segments, 2023 (%)
  • Figure 160: Teva Pharmaceuticals Revenues, 2021-2023 (USD Million)
  • Figure 161: Teva Pharmaceuticals Revenue , By Geographical Segments, 2023 (%)
  • Figure 162: GSK PLC Revenue, 2021-2023 (USD Million)
  • Figure 163: GSK PLC Revenue , By Business Segments, 2023 (%)
  • Figure 164: GSK PLC Revenue, By Geography Segment, 2023 (%)
  • Figure 165: AstraZeneca PLC Revenues, 2021-2023 (USD Million)
  • Figure 166: AstraZeneca PLC Revenues, By Geographic Segments, 2023 (%)
  • Figure 167: AstraZeneca PLC Revenue , By Business Segments, 2023 (%)
  • Figure 168: Bayer AG Revenues 2021-2023(USD Million)
  • Figure 169: Bayer AG Revenues, By Geographic Segments, 2023 (%)
  • Figure 170: Bayer AG Revenues, By Business Segments, 2023 (%)

List of Tables

  • Table A1: Global Impact of Macro Economic Factors, By Region
  • Table A2: Top exporters of Asbestos by country in 2021
  • Table A3: Top Importer of Asbestos by country in 2021
  • Table A4: United States Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A5: United States Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A6: United States Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A7: United States Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A8: United States Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A9: United States Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A10: Canada Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A11: Canada Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A12: Canada Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A13: Canada Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A14: Canada Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A15: Canada Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A16: Rest of Americas Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A17: Rest of Americas Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A18: Rest of Americas Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A19: Rest of Americas Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A20: Rest of Americas Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A21: Rest of Americas Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A22: United Kingdom Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A23: United Kingdom Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A24: United Kingdom Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A25: United Kingdom Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A26: United Kingdom Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A27: United Kingdom Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A28: Germany Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A29: Germany Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A30: Germany Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A31: Germany Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A32: Germany Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A33: Germany Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A34: France Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A35: France Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A36: France Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A37: France Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A38: France Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A39: France Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A40: Italy Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A41: Italy Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A42: Italy Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A43: Italy Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A44: Italy Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A45: Italy Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A46: Spain Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A47: Spain Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A48: Spain Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A49: Spain Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A50: Spain Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A51: Spain Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A52: Rest of Europe Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A53: Rest of Europe Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A54: Rest of Europe Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A55: Rest of Europe Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A56: Rest of Europe Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A57: Rest of Europe Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A58: China Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A59: China Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A60: China Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A61: China Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A62: China Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A63: China Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A64: India Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A65: India Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A66: India Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A67: India Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A68: India Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A69: India Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A70: Japan Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A71: Japan Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A72: Japan Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A73: Japan Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A74: Japan Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A75: Japan Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A76: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2020-2023 (USD Million)
  • Table A77: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Drug Type, By Value, 2025-2030 (USD Million)
  • Table A78: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2020-2023 (USD Million)
  • Table A79: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Route of Administration, By Value, 2025-2030 (USD Million)
  • Table A80: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2020-2023 (USD Million)
  • Table A81: Rest of Asia Pacific Malignant Pleural Mesothelioma Market, By Distribution Channel, By Value, 2025-2030 (USD Million)
  • Table A82: Bristol Myers Squibb Key Financials, 2021-2023
  • Table A83: Roche Key Financials, 2021-2023
  • Table A84: Merck & Co., Inc. Key Financials, 2021-2023
  • Table A85: Eli Lily & Co. Key Financials, 2021-2023
  • Table A86: Pfizer Key Financials, 2021-2023
  • Table A87: Novartis Key Financials, 2021-2023
  • Table A88: Teva Pharmaceuticals Key Financials, 2021-2023
  • Table A89: GSK PLC Key Financials, 2020-2022
  • Table A90: AstraZeneca PLC Key Financials, 2021-2023
  • Table A91: Bayer AG Key Financials, 2021-2023